Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
#COVID19
#Coronavirus
#PCSM
#ProstateCancer
#uroonc
consensus
coronavirus
nosocomial
pandemic
surgery
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
pubmed:
14
11
2020
medline:
17
6
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. The objective of this work is to develop guidance on criteria for prioritisation of surgery and reconfiguring management pathways for patients with non-metastatic prostate cancer who opt for surgical treatment. A second aim was to identify the infection prevention and control (IPC) measures to achieve a low likelihood of coronavirus disease 2019 (COVID-19) hazard if radical prostatectomy (RP) was to be carried out during the outbreak and whilst the disease is endemic. We conducted an accelerated consensus process and systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer. These were presented to an international prostate cancer expert panel (n = 34) through an online meeting. The consensus process underwent three rounds of survey in total. Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds. The Consensus opinion was defined as ≥80% agreement and this was used to reconfigure the prostate cancer pathways. Evidence on the delayed management of patients with prostate cancer is scarce. There was 100% agreement that prostate cancer pathways should be reconfigured and measures developed to prevent nosocomial COVID-19 for patients treated surgically. Consensus was reached on prioritisation criteria of patients for surgery and management pathways for those who have delayed treatment. IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as 'COVID-19 cold' sites. Reconfiguring management pathways for patients with prostate cancer is recommended if significant delay (>3-6 months) in surgical management is unavoidable. The mapped pathways provide guidance for such patients. The IPC processes proposed provide a framework for providing RP within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic. The broader concepts could be adapted to other indications beyond prostate cancer surgery.
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
729-741Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International.
Références
Naspro R, Da Pozzo LF. Urology in the time of corona. Nat Rev Urol 2020; 17: 251-3
Campi R, Amparore D, Capitanio U et al. Assessing the burden of nondeferrable major uro-oncologic surgery to guide prioritisation strategies during the COVID-19 pandemic: insights from three Italian high-volume referral centres. Eur Urol 2020; 78: 11-5
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 2019; 5: 1749-68
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. Version 4., 2018. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed November 2020.
Mottet N, Cornford P, van den Bergh RC, et al. EAU guidelines: prostate cancer, 2020. Available at: https://uroweb.org/guideline/prostate-cancer/. Accessed November 2020.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097
Iqbal S, Pipon-Young L. The Delphi method. Psychologist 2009; 22: 598-601
Maclennan SJ, Maclennan SJ, Imamura M et al. Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World J Urol 2011; 29: 291-301
Wolfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465-9
Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9
World Health Organization (WHO). Rational Use of Personal Protective Equipment (PPE) for Coronavirus Disease (COVID-19), 2020. Available at: https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-(ppe)-for-coronavirus-disease-(covid-19). Accessed November 2020.
Park J, Yoo SY, Ko JH et al. Infection prevention measures for surgical procedures during a middle east respiratory syndrome outbreak in a tertiary care hospital in South Korea. Sci Rep 2020; 10: 325
Lauer SA, Grantz KH, Bi Q et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577-82
National Institute of Clinical Excellence (NICE). Reducing the Risk of Transmission of COVID-19 in the Hospital Setting, 2020. Available at: https://www.nice.org.uk/covid-19/specialty-guide. Accessed November 2020.
Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing. JAMA 2020; 323: 1341-2
World Health Organization (WHO), Global Observatory for eHealth series. Telemedicine: Opportunities and Developments in Member States: Report on the Second Global Survey on eHealth, 2010. Available at: https://www.who.int/goe/publications/goe_telemedicine_2010.pdf. Accessed November 2020.
Huang Z, Zhao S, Li Z et al. The battle against coronavirus disease 2019 (COVID-19): emergency management and infection control in a radiology department. J Am Coll Radiol 2020; 17: 710-6
World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19) Situation Report - 28, 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad_2. Accessed November 2020.
Lei S, Jiang F, Su W et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 2020; 21: 100331
Wilt TJ, Jones KM, Barry MJ et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017; 377: 132-42
Bryant RJ, Oxley J, Young GJ et al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int 2020; 125: 506-14
Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33: 272-7
Ahmed HU, El-Shater Bosaily A, Brown LC et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389: 815-22
Shaw GL, Thomas BC, Dawson SN et al. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer 2014; 110: 2405-11
Fang D, Zhou L. Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers. Asia Pac J Clin Oncol 2019; 15: 108-20
Prem K, Liu Y, Russell TW et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health 2020; 5: e261-70
James ND, Spears MR, Clarke NW et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol 2016; 2: 348-57
Ng HS, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis 2018; 21: 403-10
Ribal MJ, Cornford P, Briganti A. EAU Guidelines Office Rapid Reaction Group: an organisation-wide collaborative effort to adapt the EAU guidelines recommendations to the COVID-19 era. Eur Urol 2020; 78: 21-8
Teoh JY, Ong WL, Gonzalez-Padilla D et al. A global survey on the impact of COVID-19 on urological services. Eur Urol 2000; 78: 265-75